MarketCap
Facebook
X
Telegram
FibroGen Balance Sheet 2025-2011 | FGEN
Brief overview of FibroGen's balance sheet strength
The review uses the five latest available annual reports between 2021 and 2025.
The asset base decreased -84.5%, from $773.8 million to $119.6 million. Resources became smaller over the five periods.
Asset growth of -84.5% was close to the -78.9% change in liabilities, leaving the funding profile broadly stable.
Shareholders' capital is negative, making the balance sheet dependent on consistent debt servicing capacity.
Cash equals 40% of the balance sheet, compared with 22.1% five periods ago. This is the readily available cushion.
Retained earnings remain negative at -$1.7 billion. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
What the balance sheet shows
Taken together, FibroGen's balance sheet indicators point to elevated risk. Asset growth does not offset weak funding sources.
Annual Balance Sheet FibroGen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
27.1 M | -50.4 M | -68.8 M | -145 M | -160 M | -652 M | -75.2 M | 7.9 M | -576 M | -76.4 M | -56.3 M | -68.2 M | 20.5 M | 54.4 M | - |
Long Term Debt |
75 M | 70 K | 103 K | 137 K | 3 K | 25.4 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | 12.6 M | 10.3 M | 10.9 M | 1.19 M | 983 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 219 M | 263 M | 239 M | 229 M | 207 M | 180 M | 152 M | 120 M | - |
Total Current Liabilities |
29.2 M | 133 M | 218 M | 274 M | 225 M | 163 M | 103 M | 89 M | 77.3 M | 65.1 M | 67.2 M | - | - | - | - |
Total Liabilities |
115 M | 398 M | 586 M | 612 M | 545 M | 385 M | 322 M | 352 M | 316 M | 294 M | 274 M | 243 M | 189 M | 143 M | - |
Deferred Revenue |
5.31 M | 27.3 M | 12.7 M | 12.7 M | 15.9 M | 21.7 M | 490 K | 13.8 M | 7.97 M | 7.99 M | 12.7 M | 9.22 M | 5.74 M | 2.39 M | - |
Retained Earnings |
-1.71 B | -1.89 B | -1.84 B | -1.56 B | -1.26 B | -974 M | -785 M | -716 M | -596 M | -470 M | -408 M | -322 M | -263 M | -248 M | - |
Total Assets |
120 M | 215 M | 424 M | 610 M | 774 M | 827 M | 857 M | 881 M | 899 M | 470 M | 471 M | 484 M | 297 M | 266 M | - |
Cash and Cash Equivalents |
47.9 M | 50.5 M | 81.6 M | 156 M | 171 M | 678 M | 126 M | 89.3 M | 674 M | 174 M | 153 M | 165 M | 76.3 M | - | - |
Book Value |
4.48 M | -184 M | -162 M | -1.48 M | 229 M | 441 M | 535 M | 528 M | 582 M | 175 M | 197 M | 241 M | 108 M | 122 M | - |
Total Shareholders Equity |
-30 M | -226 M | -204 M | -21.4 M | 229 M | 441 M | 516 M | 509 M | 563 M | 156 M | 178 M | 241 M | -60.8 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet FibroGen
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
75 M | 75 M | 75 M | 75 M | - | - | - | 707 K | 58.4 M | 62.5 M | 66.5 M | 70 M | 73.8 M | 76.9 M | 79.6 M | 81.1 M | 83.1 M | 85.9 M | 88.8 M | 5 K | 6 K | 22.2 M | 25.4 M | 25.4 M | 25.4 M | 25.4 M | 37.6 M | 40.7 M | 43.8 M | 46.8 M | - | - | - | - | 97.8 M | 97.8 M | 97.8 M | 97.8 M | 97.4 M | 97.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
115 M | 119 M | 398 M | 120 M | 359 M | 340 M | 398 M | 466 M | 484 M | 552 M | 586 M | 576 M | 575 M | 567 M | 612 M | 563 M | 563 M | 568 M | 545 M | 505 M | 529 M | 397 M | 385 M | 385 M | 385 M | 385 M | 322 M | 280 M | 267 M | 304 M | 352 M | 352 M | 352 M | 352 M | 351 M | 351 M | 351 M | 351 M | 294 M | 294 M | 294 M | 294 M | 274 M | 274 M | 274 M | 274 M | 243 M | 243 M | 243 M | 243 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
5.31 M | 5.68 M | 27.3 M | 5.1 M | 27.3 M | 22.5 M | 27.3 M | 28.9 M | 9.55 M | 12.9 M | 12.7 M | 7.32 M | 7.49 M | 16.5 M | 12.7 M | 7.36 M | 6.9 M | 4.74 M | 15.9 M | 23.3 M | 25.2 M | 10.7 M | 6.55 M | 6.55 M | 6.55 M | 6.55 M | 490 K | 257 K | 136 K | 12.1 M | 13.8 M | 13.8 M | 13.8 M | 16.9 M | 16.7 M | 7.97 M | 7.98 M | 7.98 M | 7.99 M | 7.99 M | 7.99 M | 7.99 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 9.22 M | 9.22 M | 9.22 M | 9.22 M | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.71 B | -1.72 B | -1.89 B | -1.69 B | -1.89 B | -1.88 B | -1.89 B | -1.91 B | -1.89 B | -1.87 B | -1.84 B | -1.79 B | -1.72 B | -1.63 B | -1.56 B | -1.49 B | -1.4 B | -1.33 B | -1.26 B | -1.13 B | -1.18 B | -1.05 B | -974 M | -974 M | -974 M | -974 M | -785 M | -687 M | -637 M | -753 M | -716 M | -716 M | -716 M | -716 M | -631 M | -631 M | -631 M | -631 M | -510 M | -470 M | -470 M | -470 M | -452 M | -408 M | -408 M | -408 M | -322 M | -322 M | -322 M | -322 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
120 M | 110 M | 215 M | 137 M | 178 M | 165 M | 215 M | 264 M | 293 M | 366 M | 424 M | 460 M | 515 M | 539 M | 610 M | 609 M | 687 M | 746 M | 774 M | 851 M | 809 M | 787 M | 827 M | 827 M | 827 M | 827 M | 857 M | 894 M | 915 M | 812 M | 881 M | 881 M | 881 M | 881 M | 899 M | 899 M | 899 M | 899 M | 470 M | 470 M | 470 M | 470 M | 471 M | 471 M | 471 M | 471 M | 484 M | 484 M | 484 M | 484 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
2.31 M | 37 M | 2 M | 118 M | 23.4 M | 33.6 M | 50.5 M | 131 M | 141 M | 106 M | 114 M | 121 M | 153 M | 189 M | 156 M | 156 M | 168 M | 186 M | 171 M | 275 M | 353 M | 434 M | 678 M | 678 M | 678 M | 678 M | 126 M | 197 M | 74.6 M | 81.7 M | 89.3 M | 89.3 M | 89.3 M | 89.3 M | 674 M | 674 M | 674 M | 674 M | 174 M | 174 M | 174 M | 174 M | 153 M | 153 M | 153 M | 153 M | 165 M | 165 M | 165 M | 165 M | 76.3 M | - | - | - | 38.9 M | - | - | - | - | - | - | - |
Book Value |
4.48 M | -9.29 M | -184 M | 17.5 M | -181 M | -175 M | -184 M | -202 M | -190 M | -186 M | -162 M | -115 M | -60.3 M | -28.9 M | -1.48 M | 46.3 M | 124 M | 178 M | 229 M | 345 M | 280 M | 390 M | 441 M | 441 M | 441 M | 441 M | 535 M | 614 M | 648 M | 508 M | 528 M | 528 M | 528 M | 528 M | 548 M | 548 M | 548 M | 548 M | 175 M | 175 M | 175 M | 175 M | 197 M | 197 M | 197 M | 197 M | 241 M | 241 M | 241 M | 241 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-205 M | -43.8 M | -184 M | -17 M | -223 M | -217 M | -226 M | -223 M | -212 M | -228 M | -204 M | -137 M | -81.8 M | -28.9 M | -21.4 M | 46.3 M | 124 M | 178 M | 209 M | 345 M | 280 M | 390 M | 441 M | 422 M | 422 M | 422 M | 516 M | 594 M | 629 M | 489 M | 509 M | 509 M | 509 M | 509 M | 528 M | 528 M | 528 M | 528 M | 156 M | 156 M | 156 M | 156 M | 178 M | 178 M | 178 M | 178 M | 221 M | 221 M | 221 M | 221 M | -60.8 M | - | - | - | -46.3 M | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of FibroGen, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
